We show iPS cell-derived CD22 CAR-NK cells efficiently kill ESCC cells in vitro, which provides proof of principle that CD22 is a potential target for ESCC CAR-NK cell treatment. This evidence concerns the gene CD22 and esophageal squamous cell carcinoma.